Area of research
Endocrinology, Diabetes and Metabolism · Physiology
Research interest
Research interests include Diabetes Treatment and Management, Nitric Oxide and Endothelin Effects, Cardiovascular Function and Risk Factors, and Diabetes, Cardiovascular Risks, and Lipoproteins.
Defining patient-reported outcomes in diabetes, obesity, cardiovascular disease, and chronic kidney disease for clinical practice guidelines - perspectives of the taskforce of the Guideline Workshop
Obesity and its management in primary care setting
Diabetic Myocardial Disorder. A Clinical Consensus Statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases
Repressive H3K27me3 drives hyperglycemia-induced oxidative and inflammatory transcriptional programs in human endothelium
Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries
Phenotyping Patients with Chronic Obstructive Pulmonary Disease and Heart Failure
Patient Phenotype Profiling in Heart Failure with Preserved Ejection Fraction to Guide Therapeutic Decision Making. A Scientific Statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension
Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
Aldosterone and aldosterone synthase inhibitors in cardiorenal disease
Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table
Telemedicine for diabetes management during COVID-19: what we have learnt, what and how to implement
Cardio‐renal‐metabolic disease in primary care setting
Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop
The Relationship between COVID-19 and Hypothalamic–Pituitary–Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess—The CAPISCO International Expert Panel
Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Post-COVID syndrome, inflammation, and diabetes
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus
Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population
Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial
Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: the ESC-EORP CICD-LT registry
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from <scp>VERTIS CV</scp> , a randomized trial of the <scp>sodium‐glucose cotransporter‐2</scp> inhibitor ertugliflozin
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial
Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management
Cardiac, renal, and metabolic effects of sodium–glucose co‐transporter 2 inhibitors: a position paper from the European Society of Cardiology ad‐hoc task force on sodium–glucose co‐transporter 2 inhibitors
Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel
Use of <scp>sodium–glucose</scp> co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry
Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020
Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: the ESC-EORP CICD-LT registry
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes